Item 7.01. Regulation FD Disclosure.

Heat Biologics, Inc. (the "Company") unveiled its new RapidVax® cellular vaccine platform at the 2021 World Vaccine & Immunotherapy Antiviral Congress. RapidVax is designed as a rapid programmable vaccine affording the Company the ability to target a comprehensive range of emerging biological threats. The Company is showcasing a poster presentation highlighting RapidVax at the World Vaccine & Immunotherapy Congress West Coast and World Antiviral Congress, November 30 to December 2, 2021, titled 'RapidVax®'- A Novel Cellular Vaccine Platform To Target Rapidly Emerging Biological Threats.

The information in this Item 7.01 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.




Item 8.01. Other Events

The Company unveiled its new RapidVax® cellular vaccine platform at the 2021 World Vaccine & Immunotherapy Antiviral Congress. RapidVax is designed as a rapid programmable vaccine to target a comprehensive range of emerging biological threats. The Company is showcasing a poster presentation highlighting RapidVax at the World Vaccine & Immunotherapy Congress West Coast and World Antiviral Congress, November 30 to December 2, 2021, titled 'RapidVax®'- A Novel Cellular Vaccine Platform To Target Rapidly Emerging Biological Threats. RapidVax leverages the immune-activating properties of heat shock protein gp96, a danger-signal associated protein. A copy of the poster presentation is attached as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits.



Exhibit
 Number    Description

  99.1       Presentation titled 'RapidVax®'- A Novel Cellular Vaccine Platform
           To Target Rapidly Emerging Biological Threats
  104      Cover Page Interactive Data File (the cover page XBRL tags are
           embedded within the inline XBRL document)

© Edgar Online, source Glimpses